Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
67 hedge funds and large institutions have $468M invested in Akero Therapeutics in 2020 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 9 closing their positions.
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
44% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 16
18% more funds holding
Funds holding: 57 → 67 (+10)
11% more capital invested
Capital invested by funds: $422M → $468M (+$46M)
10.58% more ownership
Funds ownership: 66.53% → 77.1% (+11%)
91% less call options, than puts
Call options by funds: $324K | Put options by funds: $3.48M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
+$58.7M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
+$17.3M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.7M |
| 4 |
Alkeon Capital Management
New York
|
+$10.4M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$7.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VP
venBio Partners
San Francisco,
California
|
-$17M |
| 2 |
RG
Redmile Group
San Francisco,
California
|
-$12.8M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$12M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$5.47M |
| 5 |
BI
BVF Inc
San Francisco,
California
|
-$3.61M |
AKRO Hedge Fund Activity: Q1 2020 in Review
67 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q1 2020, worth a combined $468M — up 11% from $422M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new AKRO positions and 9 closed out — a net gain of 10 holders — while 23 added to existing stakes and 16 trimmed.
The largest buyer was Versant Venture Management, opening a new position worth an estimated $58.7M. The largest seller was venBio Partners, cutting an estimated $17M.
- 67 institutional investors held Akero Therapeutics (AKRO) as of Q1 2020, up from 57 in Q4 2019.
- Funds reported $468M of Akero Therapeutics stock for Q1 2020, up 11% quarter-over-quarter.
- 19 funds opened new Akero Therapeutics positions in Q1 2020 and 9 closed out, a net change of +10 holders.
- The largest Akero Therapeutics buyer in Q1 2020 was Versant Venture Management, an estimated $58.7M added.
- The largest Akero Therapeutics seller in Q1 2020 was venBio Partners, an estimated $17M sold.
Based on aggregated 13F filings for Q1 2020.